Company Overview

Cosmos Health Inc. is a vertically integrated pharmaceutical and nutraceutical company focused on the distribution, commercialization, and development of healthcare products. The company operates primarily within the pharmaceutical distribution, nutraceutical, and branded generics segments, serving pharmacies, hospitals, and healthcare providers. Its business model combines wholesale distribution with proprietary product development, positioning the company across both regulated pharmaceuticals and consumer health products.

The company’s primary revenue drivers include pharmaceutical wholesale distribution, sales of branded nutraceutical products, and licensing or commercialization of proprietary formulations. Cosmos Health serves customers mainly in Europe and North America, with a strategic emphasis on regulated markets where pharmaceutical supply chain reliability is critical. The company traces its origins to operations in Greece and expanded internationally following its public listing in the United States, evolving from a regional distributor into a diversified healthcare platform with vertically integrated capabilities.

Business Operations

Cosmos Health generates revenue through two principal operating segments: Pharmaceutical Distribution and Nutraceutical & Branded Healthcare Products. The pharmaceutical distribution segment focuses on the wholesale supply of prescription and over-the-counter medicines, primarily through its subsidiary CosmoFarm S.A., which distributes products to pharmacies and healthcare institutions. This segment represents the company’s historically core business and largest source of recurring revenue.

The nutraceutical and branded healthcare segment includes proprietary dietary supplements, medical devices, and branded generics marketed under in-house labels. These products are distributed through both wholesale and direct-to-business channels. Operations span domestic activities in Greece and international markets, supported by owned inventory, regulatory licenses, and distribution infrastructure. The company also leverages third-party manufacturing while retaining control over branding, formulation, and commercialization.

Strategic Position & Investments

Cosmos Health’s strategic direction emphasizes vertical integration, margin expansion through proprietary products, and selective acquisitions to broaden its product portfolio and geographic reach. The company has pursued investments in branded generics, dietary supplements, and healthcare-related intellectual property to reduce reliance on low-margin distribution activities and enhance long-term profitability.

Notable strategic moves include acquisitions of pharmaceutical product rights and investments in subsidiaries that support manufacturing, licensing, and commercialization. The company has also explored opportunities in emerging healthcare sectors such as specialty generics, medical cannabis-related products, and telehealth-adjacent services, though the scale and commercial impact of these initiatives vary by market. Where disclosures are limited, the financial contribution of newer investments remains inconclusive based on available public sources.

Geographic Footprint

Cosmos Health maintains its operational foundation in Europe, with a strong presence in Greece, where its primary distribution activities, regulatory licenses, and logistics infrastructure are based. The company’s European operations serve as the backbone for pharmaceutical wholesale activities and act as a gateway for expansion into other regulated markets within the region.

Internationally, Cosmos Health has expanded into North America, supported by its corporate headquarters in the United States and its listing on a U.S. public exchange. The company’s global footprint also includes commercial relationships and sourcing activities across multiple continents, reflecting an international supply chain and diversified customer base, though revenue concentration remains weighted toward European markets.

Leadership & Governance

Cosmos Health was founded and continues to be led by its original founder, who maintains significant influence over the company’s strategic vision. The leadership team emphasizes growth through acquisition, vertical integration, and expansion of proprietary healthcare products, with a governance structure aligned to entrepreneurial decision-making and international expansion.

Key executives include:

• Gregory Siokas – Chief Executive Officer
• George Mousios – Chief Financial Officer
• Ioannis Tsalikidis – Chief Operating Officer
• Petros Galanis – Director

The leadership philosophy centers on leveraging industry experience in pharmaceutical distribution and healthcare commercialization to build a diversified, scalable healthcare enterprise, while maintaining regulatory compliance across multiple jurisdictions.